PSR: the Orphan Drug Expert
The development of drug and biological products intended to treat rare diseases is one of the fastest growing areas of clinical research and one of the most challenging, particularly for drug developers entering the orphan field for the first time. Orphan drug development presents fundamentally different regulatory and operational challenges than traditional drug development and involves interest of different stakeholders, including individual patients, rare disease patient groups, key opinion leaders, government bodies and payors.
PSR is the leading expert in orphan drug development. We assist our clients to design and execute successful clinical development strategies for orphan indications. We are specialized in complex clinical development programs requiring innovative regulatory and clinical approaches.
Agility Clinical Partners with PSR Orphan Drug Experts.
PSR Group supports Rare Disease Day 2013 by participating as a team in the Amsterdam City Swim in September 2013 !!